US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
Abionyx Pharma (0RAG) 銘柄情報

Abionyx Pharma (0RAG)

2.03

0.00

(0.00%)

終了 6月11日 12:30AM

Abionyx Pharma (0RAG) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

2.03

( - )

買値

2.03

売値

2.03

出来高

0.00

0.00 日の範囲 0.00

2.03 52 週間の範囲 2.03

時価総額

前日終値

2.03

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

151,055 €

発行済株式数

35,293,050

配当利回り

PER

-17.13

1 株当たり利益 (EPS)

-0.16

歳入

4.06M

純利益

-5.55M

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (... ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of sepsis. It is also developing ABNX-100, a strategic extension into ophthalmology of CER-001 that is in preclinical trial for the treatment of uveitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was incorporated in 2005 and is headquartered in Balma, France. 詳細を表示

セクター

-

業界

-

ウェブサイト

abionyx.com

本社

Balma, France

設立

2026

Abionyx Pharma is listed in the sector of the ロンドン証券取引所 with ticker 0RAG. The last closing price for Abionyx Pharma was 2.03 €. Over the last year, Abionyx Pharma shares have traded in a share price range of 2.03 € to 2.03 €.

Abionyx Pharma currently has 35,293,050 shares in issue. The market capitalisation of Abionyx Pharma is 71.64 € million. Abionyx Pharma has a price to earnings ratio (PE ratio) of -17.13.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	2.03	2.03	2.03	355	2.03	DE
52	0	0	2.03	2.03	2.03	4832	2.03	DE
156	0	0	2.03	2.03	2.03	1745	2.03	DE
260	0	0	2.03	2.03	2.03	1490	2.03	DE

0RAG - Frequently Asked Questions (FAQ)

What is the current Abionyx Pharma share price?

The current share price of Abionyx Pharma is 2.03 €

How many Abionyx Pharma shares are in issue?

Abionyx Pharma has 35,293,050 shares in issue

What is the market cap of Abionyx Pharma?

The market capitalisation of Abionyx Pharma is EUR 71.64M

What is the 1 year trading range for Abionyx Pharma share price?

Abionyx Pharma has traded in the range of 2.03 € to 2.03 € during the past year

What is the PE ratio of Abionyx Pharma?

The price to earnings ratio of Abionyx Pharma is -17.13

What is the cash to sales ratio of Abionyx Pharma?

The cash to sales ratio of Abionyx Pharma is 23.8

What is the registered address of Abionyx Pharma?

The registered address for Abionyx Pharma is Building D2, Balma, Midi-Pyrénées, 31130

What is the Abionyx Pharma website address?

The website address for Abionyx Pharma is abionyx.com

Monksdream

Monksdream 2分前

About

Megan Holdings Ltd. engages in the development, construction, and maintenance of aquaculture farms and related works. It offers upgrading and maintenance of aquaculture and agriculture farms, design and development of new aquaculture and agriculture farms, and the sourci

9Coastal

9Coastal 2分前

A welcome reiteration to not jump ship!

Thank you

flipper44

flipper44 2分前

See my more recent follow up posts.

The_Gman

The_Gman 3分前

Rare Earth Stocks Show Resilient Long-Term Momentum Despite Broad Monthly Pullback By Mill Chart
https://www.chartmill.com/news/HBM/Chartmill-49665-Rare-Earth-Stocks-Show-Resilient-Long-Term-Momentum-Despite-Broad-Monthly-Pullback
Rare earth stocks have pulled back broadly over the pas

exostatic

exostatic 3分前

To bad you did not sign your timely release... So for you, you are correct, no value is coming for you... If you signed you knew that value was coming some time in the future. If you followed this board even slightly you could not feel nothing is coming back (imho). So YES this makes you a hater

peanutz

peanutz 3分前

All in all not a bad day here . On watch 👀

KngmAz

Don't worry - the smart people know what we have with BIEI and we are NOT selling.

Whalatane

Whalatane 4分前

The Kidney Patient act is supposed to extend TDAPA from 2 yrs to 3 yrs .
So if that happened Velphoro would still be in TDAPA for 1 more year ( 2027 ) ....then only OLC would be in TDAPA for yrs 2028 and 2029 but compete with Velphoro in 2027
So I assume it would slow uptake of OLC

sentiment_stocks

sentiment_stocks 5分前

What with the length this MAA process is taking, I think Stillwell is simply examining some of the different pathways an approval could take. As for GZ, I think that while he works for the company, he, and even DI are not in the most inner circle dealing with the MHRA, so yes, I agree that GZ is li

Golden Cross

Golden Cross 5分前

$MMA Loading more AH's and PM ~ Major Catalysts! $1+ Incoming Here!

learningcurve2020

learningcurve2020 6分前

GuruGary can start his own NWBO centric site just like Danish. Hey Gary, why don’t you try doing a podcast. Three hours a day just like Rogan on all things NWBO / EDEN. If anyone can do it you can!

Golden Cross

Golden Cross 6分前

$MMA Loading more AH's and PM ~ Major Catalysts! $1+ Incoming Here!

EmpressRealm45

EmpressRealm45 8分前

We are easily $100+ based on $1T valuation even wiyj 80% dilution . GLTA!

OMOLIVES

OMOLIVES 12分前

He's playing it like it is. It just consolidated and went through a volume pitch like so many do. There weren't any shares and it got played up for a quick exit. You wouldn't understand because it was a quick trade on manipulation-only.

GTF

Most likely short sellers knowing the OD increases by 117% Friday. Why anybody thinks this is good for the shareholders is beyond my belief.

Lime Time

Lime Time 13分前

There will always be a younger and hungrier custodian than Sharp. May he RIP but this ticker continues on. If Hawkins is eyeing this up, we see .50 or $1 easily. Best to load these at .0001 NV SoS huge potential. Zero dilution here for decades. This can exist forever.

peafunke

peafunke 14分前

Wasn’t meant to be a comparison. Just excited as much as I can be with the potential. GLTUs

OMOLIVES

OMOLIVES 15分前

It's an advert on repeat cycle. Can't stop using the word "thematic" as well...lol. What a pathetic loser as a Company

Mark

DeadCellShadix

DeadCellShadix 15分前

In NCT $3.50 for shiggles

Forensics888

Forensics888 16分前

It's a very general statement - could mean anything. "I have a right to sell it" - explain in detail and then we have something or just more fodder. Wall street hates guessing - just look at the stock price and you see what indecision and word games get us.

WebSlinger

WebSlinger 17分前

In the article, the Scumbag CEO admits that the double-hybrid system isn't ready:
"Our double-hybrid production system is coming online shortly."
So the double-hybrid system has been perpetually "coming soon" for almost three years.

https://investorshub.advfn.com/boards/

PackerFanMadison608

PackerFanMadison608 17分前

Everyone needs to understand that there are people who will be overtly negative on IHUB and other platforms to spread Fear Uncertainty & Doubt (FUD) for the purposes of profiting off shorted stock or to lower the price so their limit orders hit. Trust your own instincts and keep track of the FUDDERS

vCISO

These types of people don’t just join worthless companies do they?

Hadas Berkowitz, JD, MBA, CISSP

gimmee greenbacks

gimmee greenbacks 19分前

Thanks for the DD..

BIEL

idDAX 50 Equal Weight Pr...

Vanguard ESG EUR Corpora...

BNP Paribas Easy MSCI AC...

Astra Exploration

Percheron Therapeutics

TriSalus Life Sciences

Mackenzie Core Resources...

iShares Semiconductor ETF

DAX MidSmall Cap

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。